• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles 2019
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles 2019
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Peptide-based PET quantifies target engagement of PD-L1 therapeutics

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Kumar, D.
    Lisok, A.
    Dahmane, E.
    Date
    2019
    Journal
    Journal of Clinical Investigation
    Publisher
    American Society for Clinical Investigation
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://dx.doi.org/10.1172/JCI122216
    Abstract
    Immune checkpoint therapies have shown tremendous promise in cancer therapy. However, tools to assess their target engagement, and hence the ability to predict their efficacy, have been lacking. Here, we show that target engagement and tumor-residence kinetics of antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified noninvasively. In computational docking studies, we observed that PD-L1-targeted monoclonal antibodies (atezolizumab, avelumab, and durvalumab) and a high-affinity PD-L1-binding peptide, WL12, have common interaction sites on PD-L1. Using the peptide radiotracer [64Cu]WL12 in vivo, we employed positron emission tomography (PET) imaging and biodistribution studies in multiple xenograft models and demonstrated that variable PD-L1 expression and its saturation by atezolizumab, avelumab, and durvalumab can be quantified independently of biophysical properties and pharmacokinetics of antibodies. Next, we used [64Cu]WL12 to evaluate the impact of time and dose on the unoccupied fraction of tumor PD-L1 during treatment. These quantitative measures enabled, by mathematical modeling, prediction of antibody doses needed to achieve therapeutically effective occupancy (defined as >90%). Thus, we show that peptide-based PET is a promising tool for optimizing dose and therapeutic regimens employing PD-L1 checkpoint antibodies, and can be used for improving therapeutic efficacy. Copyright 2018 American Society for Clinical Investigation. All right reserved.
    Sponsors
    We would like thank the University of Wisconsin and Washington University Cyclotron teams for 64CuCl2 production. Funding for this study was provided by Allegheny Health Network-Johns Hopkins Cancer Research Fund (to SN), NIH 1R01CA236616 (to SN), and NIH P41EB024495 (to MGP). Core resources (flow cytometry, histology, and imaging) were supported by NIH P30CA006973.
    Keyword
    programmed death ligand-1
    peptide-based PET
    drug-target engagement
    immune checkpoint therapeutics
    Cancer--Treatment
    Positron-Emission Tomography
    Identifier to cite or link to this item
    https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060855025&doi=10.1172%2fJCI122216&partnerID=40&md5=0e01ca87ec600363f7e1e39386eb90d0; http://hdl.handle.net/10713/8708
    ae974a485f413a2113503eed53cd6c53
    10.1172/JCI122216
    Scopus Count
    Collections
    UMB Open Access Articles 2019

    entitlement

    Related articles

    • Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
    • Authors: Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, Nimmagadda S
    • Issue date: 2017 Jan 29
    • Peptide-Based <sup>68</sup>Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer.
    • Authors: De Silva RA, Kumar D, Lisok A, Chatterjee S, Wharram B, Venkateswara Rao K, Mease R, Dannals RF, Pomper MG, Nimmagadda S
    • Issue date: 2018 Sep 4
    • Development of [<sup>18</sup>F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.
    • Authors: Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, Kalagadda VR, Emens LA, Pomper MG, Nimmagadda S
    • Issue date: 2019 Jan-Dec
    • PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    • Authors: Lesniak WG, Chatterjee S, Gabrielson M, Lisok A, Wharram B, Pomper MG, Nimmagadda S
    • Issue date: 2016 Sep 21
    • In Vivo Imaging of the Programmed Death Ligand 1 by <sup>18</sup>F PET.
    • Authors: González Trotter DE, Meng X, McQuade P, Rubins D, Klimas M, Zeng Z, Connolly BM, Miller PJ, O'Malley SS, Lin SA, Getty KL, Fayadat-Dilman L, Liang L, Wahlberg E, Widmark O, Ekblad C, Frejd FY, Hostetler ED, Evelhoch JL
    • Issue date: 2017 Nov
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.